BioAtla

BCAB49

Penny Stock

$1.71arrow_drop_down1.72%-$0.03

Penny Stock

BCAB49

$1.71

arrow_drop_down1.72%-$0.03

Penny Stock

Performance History

Key Stats
Open	$1.72
Prev. Close	$1.74
EPS	-2.17
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$83.86M
PE Ratio	-

	LOW	HIGH
Day Range	1.70	1.77
52 Week Range	1.14	4.02

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2.17

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About BioAtla (BCAB)

BioAtla, Inc. (BCAB) is a biopharmaceutical company that specializes in the development and commercialization of novel antibody therapeutics. The company's innovative platform technology, known as Conditionally Active Biologics (CABs), enables the creation of highly selective and potent antibody-based drugs. These drugs target specific proteins or pathways involved in disease processes, offering the potential for safer and more effective treatments.

BCAB stock has shown a steady growth trajectory over the years. The stock price history reflects the company's continuous progress in its research and development efforts. BioAtla has successfully advanced several CAB candidates into preclinical and clinical studies, demonstrating promising results in various indications, including cancer, autoimmune diseases, and infectious diseases.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Jay M. Short Ph.D.
Headquarters: San Diego
Employees: 66
Exchange: NASDAQ

Keep an eye on BioAtla

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is BioAtla's (BCAB) price per share?

The current price per share for BioAtla (BCAB) is $1.71. The stock has seen a price change of -$0.03 recently, indicating a -1.72% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for BioAtla (BCAB)?

For BioAtla (BCAB), the 52-week high is $4.02, which is 135.09% from the current price. The 52-week low is $1.14, the current price is 50% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is BioAtla (BCAB) a growth stock?

BioAtla (BCAB) has shown an average price growth of 0.41% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying BioAtla as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is BioAtla (BCAB) stock price performance year to date (YTD)?

As of the latest data, BioAtla (BCAB) has a year-to-date price change of -35.47%. Over the past month, the stock has experienced a price change of -10%. Over the last three months, the change has been 20.85%. Over the past six months, the figure is -30.49%.

help

Is BioAtla (BCAB) a profitable company?

BioAtla (BCAB) has a net income of -$123.46M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$129.69M. Furthermore, the EBITDA is -$108.88M.

help

What is the market capitalization of BioAtla (BCAB)?

BioAtla (BCAB) has a market capitalization of $83.86M. The average daily trading volume is 548.61K, indicating the stock's liquidity and investor engagement.

News

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

NON-SMALL CELL LUNG CANCER

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

CALENDAR OF EVENTS

HEALTH

5/23/2024

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting